Schreiber S, Colombel JF, Hanauer SB, Sandborn WJ, et al. Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies. Inflamm Bowel Dis 2025;31:2714-2724.
PMID: 40300779